Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5453 - Somatic and germline mutations of Chinese gastric cancer patients

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Tumour Site

Gastric Cancer

Presenters

Yusheng Wang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

Y. Wang1, W. Gu2, Y. Zhang3, K. Li4, Z. Niu5, Y. Zheng6, Q. Cui6, A. Wang7, H. Chen8, W. Shi8, K. Wang9, M. Yao6

Author affiliations

  • 1 Digestion Department, shanxi provincial cancer hospital, 030013 - Taiyuan/CN
  • 2 Medical Oncology, The people's Hospital of Nan Hai, 528000 - Nanhai/CN
  • 3 Department Of Chemotherapy, Chaozhou People's Hospital, 521000 - Chaozhou/CN
  • 4 Oncology Department, Guangdong Second Provixcial General Hospital, 510000 - Guangzhou/CN
  • 5 Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, 266003 - Qingdao/CN
  • 6 Medical Department, OrigiMed, 200000 - Shanghai/CN
  • 7 Department Of Clinical Analysis, OrigiMed, 200000 - Shanghai/CN
  • 8 Department Of Bioinformatics, OrigiMed, 200000 - Shanghai/CN
  • 9 Origimed, OrigiMed; Shulan ﴾Hangzhou﴿ Hospital, 200000 - Shanghai/CN
More

Resources

Abstract 5453

Background

Gastric cancer is a high incidence malignancy in China, but the disease is often diagnosed at an advanced stage with limited therapeutic options and poor prognosis. Unfortunately, limited progress of target and immune therapy has achieved in gastric cancer due to tumor heterogeneity and the lack of effective biomarkers in the clinical. Thus the precise understanding of gastric cancer genomic profiling is urgent for exploring clinical strategy of this malignancy.

Methods

Formalin Fixed Paraffin Embedded (FFPE) samples of 110 Chinese gastric cancer patients were collected for next-generation sequencing (NGS)-based 450 genes panel assay. Genomic alterations including single base substitution, short and long insertions/deletions, copy number variations, gene fusions and rearrangement were assessed. Microsatellite instability (MSI) status and tumor mutational burden (TMB) were also acquired by NGS algorithm.

Results

There were 71 males (64.6%) and 39 females (35.4%) diagnosed as gastric cancer with a median age of 62 years old. The most frequent genomic alterations in Chinese gastric cancer patients were revealed as TP53 (66.4%), ARID1A (18.2%), LRP1B (17.3%), CDH1 (15.5%), CCNE1 (14.5%), FAT4 (13.6%), ERBB2 (11.8%), SMAD4 (10.9%), KMT2D (10.9%), RNF43 (10.9%), TGFBR2 (10.0%), KRAS (10.0%), APC (10.0%). Some actionable aberrantly activated mutations were identified in genes such as FGFR1/2/3 (10.0%), BRCA1/2 (6.4%) and PI3K/mTOR pathway including FBXW7, MTOR, PIK3CA, PTEN, STK11, TSC1 and TSC2 (20.0%). In total, 39.1% of patients carried one or more actionable genomic alterations, which indicated the potential clinical benefits of targeted therapies for them. The percentage of patients with germline mutations was 9.1% in current cohort. These germline mutation genes were mainly in homologous recombination (HR) pathways such as BRCA1/2, ATM and BARD1.

Conclusions

In this study, 39.1% of Chinese gastric cancer patients carried actionable genomic alterations which could potentially guide and influence personalized treatments. About 9.1% patients harbored germline mutations mainly in HR pathway. All these genomic identifications in Chinese gastric cancer cohort may provide useful information on drug discovery and biomarker exploration.

Clinical trial identification

Legal entity responsible for the study

OrigiMed.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

Y. Zheng, Q. Cui, A. Wang, H. Chen, W. Shi, K. Wang, M. Yao: Employee: OrigiMed. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.